Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of pomalidomide + dexamethasone with or without elotuzumab in relapsed and refractory multiple myeloma
2014-003282-19Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of elotuzumab in multiple myeloma (MM) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression Free Survival. Started Feb 2016; status: completed.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2014-003282-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003282-19.